I'm interested in the future of Biotech stocks in the next decade. Interested to hear any thoughts on the industry and these two competitors in particular. Shire's recent acquisition of Baxalta may have a decent jab at CSL's market share of the blood fractionation and immunogolbulin market. Shire has been known to be the market leader in rare diseases. Anyone here have nay insight into this at all?
Submitted March 04, 2017 at 03:44AM by DrVavy http://ift.tt/2lpae0l
